President Donald Trump announced the nomination of Dr. Scott Gottlieb as the new U.S. Food and Drug Administration Commissioner. Gottlieb is 44, a conservative and longtime physician who also served as deputy commissioner of the FDA under President George W. Bush. Currently, Gottlieb is a partner at New Enterprise Associates, a venture capital firm.
Many in the tobacco industry see Gottlieb’s nomination as a positive move on behalf of the Trump administration and the industry as a whole. In 2012, Gottlieb wrote an opinion piece for the New York Post speaking out against the FDA’s regulation of cigars. In this piece, Gottlieb seemed to have a good understanding of the issues cigar manufacturers face when dealing with FDA regulation.
“About 85,000 Americans work in the premium cigar business, according to the industry’s main trade group,” Gottlieb wrote in his New York Post op-ed piece ‘Bam’s cigar trouble.’ “Regulators often prefer to enlarge their jurisdiction rather than tend to their chief obligations. But the FDA has been loath to accept that alternative tobacco products could pose a lower health risk than cigarettes. Under the law, it should be examining relative hazards, rather than spending its energies seeking to expand its powers.”